Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore various ways to sell your expertise and turn your knowledge into cash. Start leveraging your skills to increase your income today.
17,416 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
IBM is quietly reshaping its story with a serious quantum strategy, strong enterprise demand, and a durable dividend....
Accelerant Holdings has fallen sharply since its IPO, but a major fund just took a sizable stake. This article explai...
What if SpaceX and xAI merged to run data centers in orbit? This article breaks down how orbital compute could work, ...
When a CEO sells a sizable block of stock, investors take notice. This article breaks down the numbers behind imax so...
Investors often wonder if the memory chip darling Micron is still worth buying after a big run. This guide breaks dow...
Markets shift, and healthcare REITs face unique pressures. This guide helps you decide if it’s time dump your shares ...
Realty Income just announced a $1 billion joint venture with Apollo, expanding its real estate platform and preservin...
A fresh survey shows nearly half of workers 55 and older aren’t planning to use AI in their jobs. The piece outlines ...
Brookfield Asset Management is expanding its AI infrastructure pact with Bloom Energy to $25 billion, signaling a maj...
Microsoft’s Satya Nadella signals a data-centric AI strategy, arguing buyers must reveal proprietary know-how to unlo...
A surprise leadership change jolted Copart’s stock, sparking an intraday drop. This article breaks down the why, what...